Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score–matched cohort study

Journal of the American Academy of Dermatology(2020)10.1016/j.jaad.2020.09.084Source: DataRank Database

Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score–matched cohort study is a research paper published in Journal of the American Academy of Dermatology (2020). On theSindex it has a DataRank of 0. It has been cited 35 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

35 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 3.42)OA: closedTopics (57)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Seoyoung C. Kim ORCID,Richard Wyss,Sebastian Schneeweiß ORCID,Joseph F. Merola ORCID,Maria C. Schneeweiss ORCID

Live enrichment

PubMed:33038471 OpenAlex:https://openalex.org/W3091954147

Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital

Pfizer

National Institutes of Health

Roche

Bayer

AbbVie

Boehringer Ingelheim

Bristol Myers Squibb

Patient-Centered Outcomes Research Institute

US Food and Drug Adminstration

Vertex

FWCI

3.42

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

closedLicense: https://www.elsevier.com/legal/tdmrep-license

publisherhttps://api.elsevier.com/content/article/PII:S0190962220326852?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0190962220326852?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jaad.2020.09.084

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33038471

Fields of Study

Dermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisAllergic Rhinitis and SensitizationAdolescentAdultAgedAntibodies, Monoclonal, HumanizedBacterial InfectionsConjunctivitisDermatitis, AtopicFemaleHumansLongitudinal StudiesMaleMiddle AgedOpportunistic InfectionsPropensity ScoreRisk AssessmentSeverity of Illness IndexUnited StatesYoung Adult

MeSH Terms

AdolescentAdultAgedBacterial InfectionsConjunctivitisDermatitis, AtopicFemaleHumansLongitudinal StudiesMaleMiddle AgedOpportunistic InfectionsSeverity of Illness IndexUnited StatesRisk AssessmentYoung AdultPropensity ScoreAntibodies, Monoclonal, Humanized

Keywords

DupilumabMedicineAtopic dermatitisRelative riskDermatologyCohortInternal medicineCohort studyRetrospective cohort studyConfidence intervalSafetyMethotrexateepidemiologyConjunctivitisOpportunistic InfectionsReal-world EvidenceSerious Bacterial InfectionsImmunomodulating Drugs

Sustainable Development Goals

SDG 0: Good health and well-being

Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score–matched cohort study

FAIR Checklist

Authors (5)

Funding (11 grants)

Impact

Open Access

Topics